Becton Dickinson and (BDX) Coverage Initiated at Deutsche Bank
Stock analysts at Deutsche Bank initiated coverage on shares of Becton Dickinson and (NYSE:BDX) in a report released on Thursday, Marketbeat.com reports. The brokerage set a “buy” rating and a $280.00 price target on the medical instruments supplier’s stock. Deutsche Bank’s price target indicates a potential upside of 19.43% from the stock’s current price.
A number of other equities research analysts also recently issued reports on the stock. Morgan Stanley increased their price target on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a report on Thursday, October 4th. Wells Fargo & Co increased their price target on shares of Becton Dickinson and from $275.00 to $290.00 and gave the stock an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Barclays started coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They issued an “equal weight” rating and a $278.00 price target on the stock. KeyCorp increased their price target on shares of Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a report on Thursday, November 8th. Finally, Citigroup increased their price target on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $255.53.
Shares of Becton Dickinson and stock opened at $234.44 on Thursday. Becton Dickinson and has a 12-month low of $209.91 and a 12-month high of $265.87. The stock has a market capitalization of $64.71 billion, a PE ratio of 21.99, a PEG ratio of 1.67 and a beta of 1.21. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 0.90.
In related news, Director Timothy M. Ring sold 42,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the sale, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of the firm’s stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $245.83, for a total transaction of $511,326.40. Following the completion of the sale, the senior vice president now directly owns 4,497 shares in the company, valued at $1,105,497.51. The disclosure for this sale can be found here. Insiders sold 81,795 shares of company stock worth $19,571,318 over the last ninety days. 1.00% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in BDX. Alps Advisors Inc. grew its position in Becton Dickinson and by 35.3% during the second quarter. Alps Advisors Inc. now owns 1,307 shares of the medical instruments supplier’s stock valued at $313,000 after acquiring an additional 341 shares during the last quarter. Virginia Retirement Systems ET AL bought a new position in Becton Dickinson and during the second quarter valued at approximately $4,815,000. KBC Group NV grew its position in Becton Dickinson and by 38.2% during the second quarter. KBC Group NV now owns 77,091 shares of the medical instruments supplier’s stock valued at $18,468,000 after acquiring an additional 21,319 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in Becton Dickinson and during the second quarter valued at approximately $6,701,000. Finally, Sei Investments Co. grew its position in Becton Dickinson and by 375.5% during the second quarter. Sei Investments Co. now owns 142,450 shares of the medical instruments supplier’s stock valued at $34,127,000 after acquiring an additional 112,492 shares during the last quarter. 85.19% of the stock is currently owned by institutional investors and hedge funds.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.